Form 4: Apollomics Director Hong-Jung Chen Executes RSU Vesting

Director Hong-Jung Chen acquired 500 Class A Ordinary Shares of Apollomics Inc. through the vesting of restricted stock units.

Summary

• Director Hong-Jung Chen acquired 500 Class A Ordinary Shares on June 15, 2026.
• The acquisition resulted from the vesting of restricted stock units (RSUs).
• The transaction price for the vested shares was $0.
• Following this transaction, the director holds a total of 3,620 Class A Ordinary Shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing regarding routine equity compensation.

Positives

• Director maintains a direct equity stake in the company, aligning interests with shareholders.

Negatives

• None identified in this filing.

Risks

• None identified in this filing.

Future Outlook

The filing notes that an additional 500 shares are scheduled to vest on September 15, 2026.

Industry Context

StockSavvy.ai notes that this is a routine disclosure of equity compensation vesting for a corporate director, which is standard practice for publicly traded biotechnology companies.

Comparison to Industry Standards

• The vesting schedule and reporting are consistent with standard corporate governance practices for U.S.-listed biotech firms.

Stakeholder Impact

• Minimal impact on shareholders as this is a pre-planned equity compensation event.

Next Steps

• Final tranche of 500 RSUs scheduled to vest on September 15, 2026.

Key Dates

Keywords

Apollomics, APLM, Form 4, Insider Trading, Restricted Stock Units, Equity Compensation